<DOC>
	<DOCNO>NCT00115817</DOCNO>
	<brief_summary>The purpose study evaluate effect Atorvastatin . The investigator want find atorvastatin helpful quality . The investigator interest find medicine like atorvastatin useful even people high level bad cholesterol would like understand mechanism medicine help prevent blood vessel disease . Hypotheses : 1 . Atorvastatin reduce Rho kinase activity ( leukocyte ) rapidly , within day , patient atherosclerosis . 2 . Any decrease Rho kinase activity statin therapy accompany improvement familiar marker atherosclerosis .</brief_summary>
	<brief_title>The Effects Atorvastatin Patients With Atherosclerosis</brief_title>
	<detailed_description>The total study period approximately 14 + 28 day . There total 5 visit : screen visit , follow visit 0 , 7 , 14 28 day . ( These date may vary approximately 2 day event weekend holiday ) . At baseline visit ( day 0 ) , patient randomly assign atorvastatin 10 mg/day ( give 1 placebo pill + 1 10mg pill ) , 80 mg/day ( give 2 40mg pill ) placebo ( give 2 placebo pill ) . Subjects ask take 2 pill every day time 7 p.m. 8 p.m. , record calendar/diary side effect , miss dos , change concomitant medication , pertinent information . At visit , blood collect follow test : 1 ) Lipid profile , 2 ) C-Reactive protein , 3 ) Rho kinase expression activity leukocytes , 4 ) nitric oxide synthase ( NOS ) expression/activity platelet , 5 ) leukocyte/monocyte adhesion/migration assay . Blood hepatic muscle test ( ALT , GGT CK ) monitor side effect determine baseline 28 day clinically indicate . At visit , patient question compliance study medication side effect . All patient encourage adhere NCEP-ATPIII recommend therapeutic life style . Subjects ask resume statin medication take prior enrollment upon completion study .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Male female subject age 21 80 year Modified NCEP ATPIII guideline criterion meet initiate statin therapy Known stable atherosclerotic disease ( diagnosed coronary , peripheral carotid vascular disease ) and/or diabetes mellitus ( coronary heart disease equivalent ) Written informed consent prior primary care physician approval Inability give consent Pregnancy Inability withdraw statin therapy 6 week period Prior history intolerance statins Hepatic dysfunction ( ALT GGT &gt; 2 time upper limit normal Elevated muscle enzyme ( CK &gt; 3 time upper limit normal ) History myopathy myositis Evidence active inflammatory , infectious neoplastic disease Use cyclosporine , fibric acid derivative , nicotinic acid , erythromycin , azole antifungal , prednisone immunosuppressant Coronary artery bypass graft surgery percutaneous coronary intervention within precede 3 month Acute coronary syndrome myocardial infarction within precede 3 month History lifethreatening arrhythmias without implantable cardioverter defibrillator Severe chronic congestive heart failure Severe anemia Serum creatinine &gt; 3 mg/dl</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2007</verification_date>
</DOC>